Boaml

PM Modi's recent victories in state elections could lead to positive policy surprises, and that is a risk to underweight rating.

Tata Motors soars 4% on domestic & JLR sales, BoAML ups target

While reiterating a buy call on the stock, Bank of America Merrill Lynch has raised its target to Rs 580 from 560 on higher volume estimates. As recovery becomes visible Q2FY18 onwards (EPS CAGR of 21 percent FY16-19), it expects the valuation multiples to expand as well.

Expect Sensex companies to deliver robust profit growth: BoAML

Despite near-term GST disruption, Sanjay Mookim of Bank of America Merrill Lynch expects the Sensex to deliver robust profit growth and to achieve a 9 percent total return from here on.

Idea slips on downgrade, BoAML sees further weakness in revenue

Bank of America Merrill Lynch has downgraded Idea Cellular to underperform from neutral as it expects sustained weakness in company's revenues led by slowing revenue growth and negative operational leverage. The stock fell nearly 3 percent intraday Friday.

Demonetisation, GST keep active investors on sidelines: Mishra

Lack of clarity on the lasting macro-economic impact of notes cancellation and potential disruption from GST is keeping active investors on the sidelines, Neelkanth Mishra of Credit Suisse says.

Analysts positive on NBFCs, retail private banks after RBI move

After demonetisation, lot of borrowers, especially smaller ones, have been finding it difficult to pay their dues or instalments on time. Hence, in a relief to them, the Reserve Bank of India on Monday relaxed norms, saying it has been decided to provide an additional 60 days to lenders to convert standards assets into substandard assets.

Add utilities, pharma, staples, OMCs stocks to portfolio: BoAML

Sanjay Mookim of Bank of America Merrill Lynch says without a private capex cycle, Indian consumption is the only 'hope' in town. According to him, long-term investors may look to ride through this dip in consumer activity.

Banks sink 7% amid US polls woes; but analysts see strong growth

Banks stocks fell sharply amid steep market correction on US elections jitters. Bank Nifty crashed 7 percent intraday but analysts expect strong growth in banks going ahead, especially after the government announced measures to curb the black money.

BoAML retains buy on Aurobindo, sees 23% EPS CAGR over FY16-18

Bank of America Merrill Lynch (BoAML) has maintained its buy rating on Aurobindo Pharma on expectations of strong 23 percent earnings per share (EPS) CAGR over FY16-18, especially after USFDA's successful inspection of unit IV plant at Andhra Pradesh and establishment inspection report for Penem facilities.

Pending order pipeline, turnaround in US key for Aurobindo:BoAML

Bank of America Merrill Lynch (BoAML), in a report, says that concerns over contraction in its US business and reduction in Research & Development are main concerns for investors. Also, pursuance of expensive Mergers & Acquisitions and inferior cash conversion abilities continue to weigh on Aurobindo.

Brexit impact limited on pharma, US biz to offset risk: Analysts

Brokerage houses do not see any major impact of Brexit on pharma companies' earnings. In fact they have not changed their views post Friday's event, saying companies may get impacted only by currency volatility globally. According to them, any EU impact will offset by US large exposure to the US.

What now for UK? Brokerages give you a lowdown

Once the initial reaction cools off, the main victim will be UK‘s economy, says BOAML in a report.

Hindalco up 3%; BoAML retains buy on B/S, Novelis product mix

BoAML feels stabilising aluminum premiums and rising auto sheet volumes (fetching higher realisation) are good for Novelis' profitability.

BoML upgrades Bharti to buy led by steady growth; stock up 3%

Bharti‘s India revenue market share may be largely flat for the next four years, despite the Jio entry. BoA ML projects a FY16-19 earnings per share (EPS) CAGR of 20 percent, led by steady EBITDA growth/deleveraging.

BoAML ups target & EPS of Shriram Transport on growth, margins

According to BoAML, STFC is big beneficiary of a turnaround in the commercial vehicle cycle and its recent quarterly asset quality performance is a testament to that.

ITC up 8% post Q4, brokers raise target on cigarette rebound

With retaining outperform rating, Credit Suisse increased target price to Rs 385 from Rs 370, saying the company recorded strongest EBITDA growth in 7 quarters and cigarette business performance was the best in 11 quarters

Motherson up 2%, BoAML reiterates buy on strong growth prospect

The brokerage said Motherson India unit, contributing to 46 percent of price target, is likely to see more than 15 percent revenue growth from FY17, significantly better than 5-10 percent growth since FY14.

PI Ind jumps 4%; BoAML expects co to outperform EPS estimates

The brokerage expects PI to outperform previous FY17/18 earnings per share estimates due to structural changes leading to increased CRAMS (contract research and manufacturing services) opportunity in India, a 27 percent QoQ increase in order book in Q3FY16 and improving EBITDA margin (about 194 basis points in April-December period of FY16).

Aurobindo up 1%; gets third USFDA nod in 2 days, BoAML positive

This is third approval received by the company in the last two days. Yesterday, the company had received two approvals from USFDA to manufacture and market Celecoxib Capsules and Levetiracetam Injection USP.

Godrej Consumer up 10%, BoAML sees margin-led growth in Q2

The brokerage expects GCPL to maintain margin-led growth momentum in Q2FY16 on stable growth in domestic business (mainly led by household insecticides and hair color), and strong constant currency (CC) growth in Latin America/Africa, but weakness in Indonesia.

YES Bank up over 1%; BoAML retains buy, sees 70% upside

BoAML feels asset quality risk already priced in and is betting on retail-isation. The stock gained more than 1 percent intraday Monday.

Glenmark Pharma falls 6%; BoAML downgrades to underperform

The stock rallied 56 percent in the last six months. The brokerage believes Glenmark is fully valued at its target September 2017 P/E of 21x.

Mylan's Asthma drug launch in UK negative for Cipla: BoAML

Brokerage Bank of America Merrill Lynch (BoAML) feels the launch of asthma drug by Mylan in the UK is negative for Cipla because earlier the drug maker was expected to be the first company to launch this drug. Shares of Cipla fell nearly 2 percent in early trade Tuesday.

Bharat Forge slips 3% on BoAML downgrade, target cut too

Shares of Bharat Forge fell nearly 3 percent intraday on Friday after brokerage Bank of America Merrill Lynch (BoAML) downgraded the stock to underperform from buy.

Sun Pharma, Lupin, Cipla, Cadila plunge on BoAML downgrade

Shares of pharma majors like Sun Pharma, Lupin, Cipla and Cadila Healthcare fell 2-4 percent intraday after brokerage Bank of America Merrill Lynch (BoAML) downgraded these stocks.